Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0616A · 1 trial · 1 indication
Blood samples will be collected to determine the AUC0-inf of enlicitide in plasma
Blood samples will be collected to determine the AUC0-inf of rosuvastatin in plasma
Blood samples will be collected to determine the AUC0-last of enlicitide in plasma
Blood samples will be collected to determine the AUC0-last of rosuvastatin in plasma
Blood samples will be collected to determine the cmax of enlicitide in plasma
Blood samples will be collected to determine the cmax of rosuvastatin in plasma
| Arm | Type | Description |
|---|---|---|
| Enlicitide + Rosuvastatin Part 1 | EXPERIMENTAL | Participants in Part 1 will receive a single dose of enlicitide tablet coadministered with a single dose of rosuvastatin tablet |
| MK-0616A Part 1 | EXPERIMENTAL | Participants in Part 1 will receive a single dose of MK-0616A |
| Enlicitide + Rosuvastatin Part 2 | EXPERIMENTAL | Participants in Part 2 will receive a single dose of enlicitide tablet coadministered with a single dose of rosuvastatin tablet |
| MK-0616A Part 2 | EXPERIMENTAL | Participants in Part 2 will receive a single dose of MK-0616A formulation B |
| Name | Type | Description |
|---|---|---|
| MK-0616A | DRUG | Enlicitide/rosuvastatin fixed dose combination (FDC) or enlicitide/rosuvastatin FDC formulation B oral tablets |
| Enlicitide | DRUG | Oral tablet |
| Rosuvastatin | DRUG | Oral tablet |
The main inclusion criteria include but are not limited to the following: * Is medically healthy with no clinically significant medical history * Is a non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to study entry Exclusion Criteria: * Is unable t...
MK-0616A is an investigational small molecule being developed by Merck & Company, Inc. (ticker MRK). It is in Phase 1 clinical development, and the specific therapeutic indication has not been disclosed. One Phase 1 trial has been registered for the program, and that trial is currently active.
MK-0616A is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the registered Phase 1 clinical trial for this small molecule asset. The program remains in early clinical development.
MK-0616A is in Phase 1 clinical development. One Phase 1 trial has been registered for the program, and it is currently active and not recruiting. No later-phase trials for MK-0616A have been registered.
MK-0616A is being studied in one registered Phase 1 trial, NCT07300280, titled A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039). The trial is active but not recruiting, is controlled, and is being conducted in the United States.
The Phase 1 trial of MK-0616A, NCT07300280, has an enrollment of 60 participants. It is a controlled, randomized trial that is not double blind and enrolls healthy adult volunteers age 18 and older, both male and female, in the United States.